A Novel Quaternary Structure of the Dimeric alpha -Crystallin Domain with Chaperone-like Activity*

Ingeborg K. FeilDagger §, Marc MalfoisDagger , Jörg HendleDagger , Hans van der Zandt, and Dmitri I. SvergunDagger ||**

From the Dagger  European Molecular Biology Laboratory (EMBL), EMBL Hamburg Outstation, Notkestrasse 85, D-22603 Hamburg, Germany,  EMBL, EMBL Heidelberg, Protein Expression and Purification Unit, Meyerhofsrasse 1, D-69012 Heidelberg, Germany, and || Institute of Crystallography, Russian Academy of Sciences, Leninsky pr. 59, 117333 Moscow, Russia

Received for publication, December 1, 2000, and in revised form, January 12, 2001



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

alpha B-crystallin, a member of the small heat-shock protein family and a major eye lens protein, is a high molecular mass assembly and can act as a molecular chaperone. We report a synchrotron radiation x-ray solution scattering study of a truncation mutant from the human alpha B-crystallin (alpha B57-157), a dimeric protein that comprises the alpha -crystallin domain of the alpha B-crystallin and retains a significant chaperone-like activity. According to the sequence analysis (more than 23% identity), the monomeric fold of the alpha -crystallin domain should be close to that of the small heat-shock protein from Methanococcus jannaschii (MjHSP16.5). The theoretical scattering pattern computed from the crystallographic model of the dimeric MjHSP16.5 deviates significantly from the experimental scattering by the alpha -crystallin domain, pointing to different quaternary structures of the two proteins. A rigid body modeling against the solution scattering data yields a model of the alpha -crystallin domain revealing a new dimerization interface. The latter consists of a strand-turn-strand motif contributed by each of the monomers, which form a four-stranded, antiparallel, intersubunit composite beta -sheet. This model agrees with the recent spin labeling results and suggests that the alpha B-crystallin is composed by flexible building units with an extended surface area. This flexibility may be important for biological activity and for the formation of alpha B-crystallin complexes of variable sizes and compositions.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

alpha A- and alpha B-crystallin, which share 54% amino acid sequence identity, build the subunits of alpha -crystallin, a major eye lens protein, comprising up to 40% of the total lens proteins. The structural function of the alpha -crystallin is to assist in maintaining transparency in the lens (1). The chaperone-like function of alpha B-crystallin helps to avoid formation of large light-scattering aggregates and possibly helps to prevent cataract in the lens. Moreover, neurodegenerative diseases, ischemia, or multiple sclerosis lead to an overexpression of this protein, which makes it an object of special medical interest (2).

The alpha -crystallin as well as other mammalian small heat-shock proteins (sHSPs)1 form large globular complexes with a diameter of about 10-25 nm. Cryoelectron microscopy and image analysis revealed that alpha B-crystallin is a hollow spherical shell with variable quaternary structure (3), and a frequent exchange of subunits between the particles was observed. The chaperone activity of alpha B-crystallin is associated with partial perturbation of the substrate protein tertiary structure, leading to a multimeric molten globule-like state with increased hydrophobicity (4, 5). The exposed hydrophobic regions of alpha -crystallin interact with substrate proteins possessing an increased surface hydrophobicity but a low degree of unfolding (6).

The molecular structure and subunit interactions in alpha -crystallin have long been under investigation. The stretches of residues promoting formation of lower or higher molecular weight alpha -crystallin oligomers have been identified. Upon addition of 1% deoxycholic acid, the alpha -crystallin oligomer dissociates into tetramers (7). The latter can also be formed by deletion of amino acids 1-63 in alpha A-crystallin (8). Site-directed spin-labeling demonstrated that the alpha A-crystallin dimers are formed by subunit interactions along a highly conserved beta -strand in the region of residues 109-121 (9). This stretch of residues forms a sheet of two antiparallel beta -strands that extends across the dimer interface.

The oligomers of bacterial sHSPs are monodisperse and more rigid. Their gel filtration profile shows a single narrow, symmetric peak, whereas alpha -crystallin, alpha B-crystallin, or HSP27 yield broader peaks (10). A 2.9 Å resolution crystal structure of MjHSP16.5, a sHSP isolated from a hyperthermophilic archaeon, has been determined (11). The topology of the MjHSP16.5 monomer resembles an immunoglobulin fold with a central beta -sandwich of two sheets, consisting of four beta -strands each. Upon dimerization, one of the sheets is extended by an additional strand contributed by the neighboring subunit (Fig. 1, left panel). This fifth strand labeled beta 6 (11), a small stretch of five residues from 93 to 97, is part of a long loop of 19 residues (84) protruding into the structural core of the monomer. This strand is therefore crucial for the stabilization of the MjHSP16.5 dimer.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Left panel, x-ray structure of the MjHSP16.5 dimer in two perpendicular orientations. The green and red monomers of MjHSP16.5 and the alpha -crystallin domain, respectively, are in the same orientation. The strand-strand interaction at the dimer interface is indicated by orange spheres. Right panel, V-shaped model of the alpha -crystallin domain dimer obtained by rigid body refinement in two perpendicular orientations.

A dimeric model of the alpha -crystallin domain has recently been generated (12) by homology modeling based on the crystal structure of MjHSP16.5. The quaternary structure of the homology model and thus the dimeric interface are virtually identical to those of MjHSP16.5 displayed in Fig. 1, left panel. The loop-strand-loop motif (residues 84-102 of subunit A) interacting with strand beta 2 (residues 45-49 of subunit B) in MjHSP16.5 has been modeled in human alpha B-crystallin as a large loop lacking secondary structure (residues 104-115 of subunit A) that is adjacent to strand beta 2 (residues 66-70 of subunit B). The homology model (12) does not show contacts between residues 114-118 in subunits A and B, and this contradicts the spin-labeling results (9).

The present study is aimed at the analysis of the properties and structure of the alpha -crystallin domain of the human alpha B-crystallin. A dimeric alpha -crystallin domain is expressed, purified, and characterized using different biochemical and physical methods. Its quaternary structure is studied by synchrotron radiation x-ray scattering. The latter method allows us to determine overall structures of native biological macromolecules under nearly physiological conditions (13). Comparisons between experimental x-ray solution scattering curves and those evaluated from crystallographic structures are widely used to verify structural similarity between macromolecules in crystals and in solution (14, 15). Moreover, the use of crystallographic models of individual subunits permits the building of structural models of complex particles in solution by rigid body refinement against the scattering data (16-18). Below, solution scattering is used to demonstrate that the quaternary structure of the alpha -crystallin domain dimer differs from that of sHSP from Methanococcus jannaschii. A model of the former, constructed by rigid body refinement, displays a new dimerization interface, suggesting that the alpha -crystallin domain may be flexible in solution.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning-- The amino acid sequence alignment between human alpha B-crystallin and MjHSP16.5 was used as a basis (12). The residue Ala-57 in alpha B-crystallin was aligned with Gln-36 in MjHSP16.5, the N-terminal residue of the first beta -strand beta 1. The Arg-157 in alpha B-crystallin was aligned with Ile-144 in MjHSP16.5, located in the last beta -strand, beta 10. The sequence Ala-57 through Arg-157 covered the core alpha -crystallin domain plus an additional nine residues from the N-terminal domain. The alpha B-crystallin deletion mutant gene was excised from plasmid alpha B57+pET16b at the restriction sites NcoI and XhoI. The gene fragment was ligated into expression vector pETM-11 at the NcoI and XhoI sites. The resulting plasmid was named palpha B57-157.

Expression and Purification of the alpha -Crystallin Domain-- Plasmid palpha B57-157 was transformed into BL21(DE3), and 1-liter expression cultures were grown in Luria Broth medium supplemented with kanamycin to a final concentration of 50 µg/ml. The expression was induced at A600 = 0.8 by the addition of isopropyl-1-thio-beta -D-galactopyranoside to a final concentration of 1 mM. After 4-6 h of induction, cells were collected by centrifugation, and the cell pellets were resuspended in 50 ml of starting buffer (20 mM sodium phosphate, 0.5 M NaCl, pH 7.4). 400 µl of lysozyme (10 mg/ml; Sigma) were added to the cell suspension, and the suspension was stirred in an ice-water bath for 20 min. After the addition of 1 µl of benzonase (250 units/µl; Merck), the suspension was incubated at 23 °C for 10 min with constant stirring. Insoluble cellular debris was removed by sedimentation at 36,000 × g for 30 min at 4 °C. The supernatant was filtered through a 0.22-µm filter (Millipore). At a flow rate of 1 ml/min, 25 ml of cell extract were applied on a 1-ml Hi-Trap metal-chelating column (Pharmacia), charged with 100 mM NiCl2 solution, and equilibrated with starting buffer. The column was washed with 10 column volumes of starting buffer. For 10 column volumes, a linear gradient from 0 to 500 mM imidazole was applied. The His-tagged alpha B57-157 fusion protein eluted at 400 mM imidazole concentration. The positive fractions were pooled, and a His6-tagged TEV-protease was added in a 100:1 ratio (w/w). The cleavage reaction was dialyzed against starting buffer at 20 °C for 24 h. The reaction mixture was passed through a mini-column (Bio-Rad) filled with 1 ml of Ni-NTA resin (Qiagen), which had been equilibrated with starting buffer. The flow-through was collected and analyzed for purity on a 10% SDS-polyacrylamide gel electrophoresis (Novex) stained with Coomassie Blue or silver staining methods. Protein samples were concentrated using Centricon (Millipore) filter units with a molecular mass cutoff of 3 kDa. Protein concentrations for all measurements were determined by the Bradford method, using the Bio-Rad protein assay reagent with bovine serum albumin as a standard.

Chaperone Activity Assay-- The effect of the alpha -crystallin domain on protein aggregation was measured as described previously (19). Aggregation of alcohol dehydrogenase (ADH) at 37 °C was measured as an apparent optical density at A360 using a Kontron Uvikon 922 Spectrophotometer equipped with a thermostated cuvette holder. In a total reaction volume of 400 µl, 5 µM yeast ADH (Sigma) was incubated with varying amounts of purified alpha -crystallin domain or 1 µM human alpha B-crystallin. The reaction buffer was a 50 mM sodium phosphate buffer (pH 7.0), 0.1 M NaCl, and 2 mM EDTA. The optical density in the cell was recorded every 2 min. For all molar ratios, three independent experiments were conducted.

Sedimentation Velocity Analysis and Equilibrium Centrifugation-- A Beckman XLA analytical ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA) equipped with ultraviolet absorption optics was used for the sedimentation velocity and the sedimentation equilibrium studies at 4 °C and at 10 °C, respectively. Protein in 50 mM phosphate buffer, pH 7.0, was loaded into 12-mm double-sector aluminum cells placed in an An60 Ti rotor. For the sedimentation velocity analysis, sample volumes of 350 µl were centrifuged at 60,000 rpm. Radial scans of absorbance at 290 nm were taken at 2-min intervals. Data were analyzed to provide the apparent distribution of sedimentation coefficients by means of the programs DCDT (20) and SVEDBERG (21). The hydrodynamic modeling was done with ULTRASCAN (22).

For the sedimentation equilibrium analysis, a sample volume of 180 µl at 3 mg/ml protein in 50 mM phosphate buffer, pH 7.0, was centrifuged at 26,000 rpm. Each data point measured at 297 nm was an average of 50 measurements. The solution density (1.0029 g/ml) and the partial volume of the protein (0.7217 ml/g) were calculated with ULTRASCAN, using the known buffer composition and amino acid composition of the protein. The degree of hydration was estimated based on the amino acid composition by the method of Kuntz and Brassfield (23).

Scattering Experiments and Data Analysis-- The synchrotron radiation x-ray scattering data were collected using standard procedures on the X33 camera (24-26) of the European Molecular Biology Laboratory (EMBL) on storage ring DORIS III of the Deutsches Elektronen Synchrotron (DESY) and the multiwire proportional chambers with delay line readout (27). The solutions were measured at protein concentrations of 5, 10, and 25 mg/ml. The scattering curves were recorded at a wavelength lambda  = 0.15 nm for sample detector distance 1.4 m covering the momentum transfer range 0.40 < s < 5.1 nm-1 (s = 4pi sintheta /lambda , where 2theta is the scattering angle). The data were normalized to the intensity of the incident beam and corrected for the detector response, the scattering of the buffer was subtracted, and the difference curves were scaled for concentration using the program SAPOKO.2 The curves were extrapolated to zero concentration and merged with the data obtained at high protein concentration using standard procedures (13).

The maximum dimension Dmax of the protein was estimated from the experimental data using the orthogonal expansion program ORTOGNOM (28). The radius of gyration Rg was evaluated using the Guinier approximation, Iexp(s) = I(0)exp(-s2Rg2/3), which is valid for (sRg) < 1.3 (13), and also from the entire scattering curve using the indirect transform package GNOM (29, 30). The Porod volume (31) Vp was calculated from the experimental data as described previously (13).

The coordinates of the crystallographic model of the HSP16.5 from M. jannaschii were taken from the Protein Data Bank, entry 1shs (11). The scattering curves from the x-ray structure and the homology models were calculated using the program CRYDAM,3 a modified version of the program CRYSOL (32). The program takes into account the scattering from the solvation shell at the surface of the protein model. The latter is covered by a 0.3-nm-thick hydration layer with an adjustable density rho b, which may differ from that of the bulk solvent. The scattering intensity is
I(s)=⟨‖A<SUB>a</SUB>(s)−&rgr;<SUB>s</SUB>A<SUB>s</SUB>(s)+&dgr;&rgr;<SUB>b</SUB>A<SUB>b</SUB>(s)‖<SUP>2</SUP>⟩<SUB>&OHgr;</SUB> (Eq. 1)
where Aa(s) is the scattering amplitude from the particle in vacuo, As(s) and Ab(s) are, respectively, the scattering amplitudes from the excluded volume and the hydration layer, both with unitary density, delta rho b = rho b - rho s; and <  >  stands for the average over all particle orientations (Omega  is the solid angle in reciprocal space, s = (s, Omega )). Given the atomic coordinates, the program fits the experimental data using two free parameters, the excluded volume of the particle and the contrast of the hydration layer delta rho b, to minimize the discrepancy between the experimental and calculated curve
&khgr;<SUP>2</SUP>=<FR><NU>1</NU><DE>N−1</DE></FR> <LIM><OP>∑</OP><LL>j=1</LL><UL>N</UL></LIM> <FENCE><FR><NU>I<SUB><UP>calc</UP></SUB>(s<SUB>j</SUB>)−I<SUB><UP>exp</UP></SUB>(s<SUB>j</SUB>)</NU><DE>&sfgr;(s<SUB>j</SUB>)</DE></FR></FENCE><SUP>2</SUP> (Eq. 2)
where N is a number of the experimental points, and Iexp(s) and sigma (s) denote the experimental intensity and its S.D., respectively.

Molecular Model Building-- The x-ray structure of MjHSP16.5, Protein Data Bank entry 1shs (11), was used as a template for molecular modeling. The monomer of the alpha -crystallin domain was modeled in close structural homology to the crystal structure of MjHSP16.5, using the residues 36-144 with the exception of the dimerization motif. All models were built and energy minimized using the program O (33). The sequence alignment used in the molecular modeling is identical to that of Muchowski et al. (12), with one exception. The largest gap in the entire alignment was reduced from eight to seven residues to optimize the interaction at the putative dimer interface (Fig. 2).



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Sequence alignment between human alpha B-crystallin and M. jannaschii HSP16.5. Only the region relevant for the modeling of the dimer interface is presented, beginning with the N terminus of strand beta 5 and ending with the C terminus of strand beta 6. The secondary structure was assigned using PROMOTIF (46). The beta -strands of MjHSP16.5 are labeled as reported previously (11), and a similar labeling scheme was used for alpha B-crystallin.



    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characterization and Chaperone Activity-- The alpha -crystallin domain corresponds to the peptide 57-157 from alpha B-crystallin, which was isolated after a tryptic digest of alpha B-crystallin (34). It was the smallest peptide identified after trypsinization, which comprises the alpha -crystallin domain. With the expression of palpha B57-157 and after proteolytic cleavage of the His-tagged fusion protein, the alpha -crystallin domain had an additional three N-terminal, vector-derived amino acids (Gly, Ala, and Met). The untagged form of the alpha -crystallin domain eluted with a >98% purity in the flow-through of the Ni-NTA column (Fig. 3). Proper folding of the protein was confirmed by far-ultraviolet circular dichroism spectroscopy (Fig. 4). The spectrum showed negative ellipticity with a minimum at 215 nm, typical for a beta -sheet structure and in agreement with secondary structure predictions made for the alpha -crystallin domain of alpha B-crystallin (35-37) and with far-ultraviolet CD spectra observed for wild type alpha B-crystallin (12) and other sHSPs (38).



View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   SDS-polyacrylamide gel electrophoresis analysis of alpha -crystallin domain purification. Lane 1, marker; Lane 2, His6-tagged alpha -crystallin domain fusion protein (His6-alpha B57-157), His6-tagged TEV-protease, and alpha -crystallin domain (alpha B57-157) cleavage mixture, which was applied to the Ni-chelating column; Lanes 3-5, alpha -crystallin domain (alpha B57-157) elution fractions.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Far-ultraviolet circular dichroism spectra of the alpha -crystallin domain. Measurement was made at a protein concentration of 0.15 mg/ml in 50 mM sodium phosphate buffer, pH 7.0, using a 1-mm path length cuvette. The spectrum is the average of eight scans.

The functionality of the alpha -crystallin domain was also confirmed by the chaperone activity assay (Fig. 5). The ADH aggregation was effectively suppressed with a 5-fold molar excess of alpha -crystallin domain over ADH and was comparable to the protection by wild type alpha B-crystallin in a ratio of ADH (5 µM):alpha B-crystallin (1 µM). When comparing the aggregation values of the ADH control and ADH (5 µM):alpha -crystallin domain (5 µM) at the 32 min time point, the control showed 100% ADH aggregation, whereas the ADH in the presence of alpha -crystallin domain aggregated only to 45%. At a 10-fold molar excess of ADH over alpha -crystallin domain, no protection of ADH aggregation was observed. The decrease of absorption for ADH (5 µM) and ADH (50 µM):alpha -crystallin domain (5 µM) beyond the 34 min time point was caused by precipitation of large protein aggregates in the cuvette. With an average of 32 subunits/wild type alpha B-crystallin molecule, the protection from aggregation per dimer was 100% at a 3.2-fold molar excess of alpha B-crystallin over ADH. With the alpha -crystallin domain dimer, a 5-fold molar excess was effective in protecting the same amount of ADH. Although the chaperone activity of the wild type alpha B-crystallin dimer exceeded that of the alpha -crystallin domain dimer by about 1.5-fold, the effectiveness of the alpha -crystallin domain in preventing ADH aggregation remains high.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Functional characterization of wild type alpha B-crystallin and alpha -crystallin domain (alpha B57-157) on ADH aggregation at selected molar ratios. , ADH (5 µM):wild-type alpha B (1 µM); open circle , ADH (5 µM); black-square, ADH (50 µM):alpha B57-157 (5 µM); , ADH (5 µM):alpha B57-157 (5 µM); triangle , ADH (5 µM):alpha B57-157 (25 µM).

Solution Structure of the alpha B-Crystallin Domain-- The molecular mass of the alpha -crystallin domain estimated from the analytical ultracentrifugation (22 ± 2 kDa) indicated that the protein is dimeric in solution. The velocity sedimentation data confirmed that the solution was monodisperse. The sedimentation coefficient 1.82 ± 0.06 (s20,W) and the hydrodynamic modeling suggested that the dimer is rather elongated with an estimated axial ratio of 1:10.

The synchrotron x-ray scattering curve from the alpha -crystallin domain is presented in Fig. 6a. The maximum dimension of the particle was 7.0 ± 0.2 nm, and the radius of gyration = 2.27 ± 0.03 nm. The Porod volume (i.e. the excluded volume estimate) of 42 ± 3 nm3 was compatible with the expected excluded volume of a hydrated dimer and incompatible with a monomeric protein. It can thus be concluded that the alpha -crystallin domain is dimeric in solution, in agreement with the above-mentioned results of the analytical ultracentrifugation. The dimeric structure has been found at all protein concentrations.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 6.   A, experimental solution scattering curve of the alpha -crystallin domain of the human alpha B-crystallin and the fits calculated from the atomic models. (1), the crystallographic dimer of MjHSP16.5; (2-6), scattering from the dimeric homology models in B. The curves (1-6) are displaced down by one logarithmic unit for clarity, and the discrepancies with the experimental data are presented. B, the five alpha -crystallin domain models (2-6) tested against scattering data with increasing compactness from top to bottom. The left-hand monomer is in the same orientation for each model. The models are numbered to match the fits in A.

The comparison between the scattering curve computed from the dimeric x-ray model of the sHSP (11) (Fig. 1, left panel) and the experimental scattering curve is presented in Fig. 6a, fit (1). The two curves display noticeable systematic deviations (the discrepancy between the experimental and calculated data is chi  = 1.89). To check whether the data can be fitted by minor modifications of the crystallographic structure, several tentative models were generated by rigid body movements (up to ± 0.2 nm) and rotations (up to ± 10 degrees) of the second monomer. All these models yielded poor fits with chi  between 1.8 and 2.5. This suggests that the quaternary structure of the alpha -crystallin domain of the human alpha B-crystallin differs from that of HSP16.5 from M. jannaschii.

The focus of the molecular modeling of the alpha B-crystallin mutant was the generation of an interface between two subunits, which is in agreement with (i) the sequence alignment, (ii) the spin-labeling study (9), and (iii) the general molecular interactions involved in protein stabilization and fits the experimental scattering data. In keeping with the low resolution of solution scattering, the modeling of the dimer of alpha B-crystallin was performed in terms of rigid body movements and rotations of the monomeric subunit derived by homology modeling from the crystal structure of MjHSP16.5. The amino acid sequence of the alpha -crystallin domain of human alpha B-crystallin and MjHSP16.5 is more than 23% identical, and more than 50% of the residues are chemically similar. Furthermore, secondary structure prediction indicated a similar arrangement of secondary structure elements in both proteins (results not shown). In the crystal structure of MjHSP16.5, the strands beta 5 and beta 7 are connected by a loop-strand-loop motif ranging from residues 84-102. Within this motif, the short strand beta 6 (residues 93-97) from one subunit interacts with strand beta 2 (residues 45-49) from the neighboring subunit. The corresponding region in alpha B-crystallin was modeled as a strand-turn-strand ranging from residues 105 to 116 and designated as beta 6.1 and beta 6.2. The dimerization between the monomers takes place along strand beta 6.2, contributed by the two subunits A and B, which built a four-stranded, antiparallel, intersubunit composite beta -sheet with the following strand order: Abeta 6.1-Abeta 6.2-Bbeta 6.2-Bbeta 6.1. The modeled strands beta 6.1 and beta 6.2 are separated from beta 5 and beta 7 by one residue only, Glu-105 and Glu-117, respectively. Both residues are in a nonextended main chain dihedral conformation, resulting in a kink between the sheet made up by beta 5 and beta 7 and the beta 6.1-beta 6.2 sheet. The angle between the core beta -sandwich and the intersubunit composite sheet varies depending on the actual main chain dihedrals of Glu-105, Glu-117, and their flanking residues. Accordingly, the dimer may have a more closed, compact or a more open, elongated shape. Five different dimer models have been tested (Fig. 6b), ranging from a dimer with an open L-shape (top; (2)) to more compact structures and, finally, a V-shaped dimer (bottom; (6)). The fits to the experimental data computed by CRYDAM are presented in Fig. 6a, curves (2-6). All these models yield better fits than that provided by the crystallographic model of the MjHSP16.5 dimer (curve (1)). The most compact, V-shaped model providing the best agreement with the experimental data is also displayed in Fig. 1 (right panel) for comparison with the crystallographic model of MjHSP16.5.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Probably the most intriguing functional finding in our study of the dimeric alpha -crystallin domain from human alpha B-crystallin is that the chaperone activity does not require a multimeric alpha B-crystallin complex. The existence of two sites of interactions between sHSP monomers has been proposed previously (39). Our results confirm that after deletion of the N-terminal domain of alpha B-crystallin no large oligomers are formed and that the interaction site in the C-terminal domain promotes the assembly of a stable dimer. Unlike HSP16.2 from Caenorhabditis elegans, alpha B-crystallin maintains chaperone-like activity without its N-terminal domain and, moreover, does not require multimeric assembly to be active (40). The chaperone activity at different levels of oligomerization has also been observed for murine HSP25, a member of the mammalian sHSP family (41).

The final model of the alpha -crystallin domain dimer in Fig. 1 (right panel) provides an excellent fit to the solution scattering data in a wide angular range. A nominal resolution of the data is 1.2 nm, and details of the tertiary structure can obviously not be validated experimentally at this level of resolution, which is why we restricted ourselves to rigid body modeling. Solution scattering is rather sensitive to rigid body movements of structural domains and has successfully been used to model the quaternary structure of proteins (15-17). The use of rigid body modeling is justified by a high sequence homology between monomeric alpha B-crystallin and MjHSP16.5. Because no reasonable fit to the scattering data could be obtained in the vicinity of the crystallographic model of MjHSP16.5 (Fig. 1, left panel), the arrangement of the monomers as shown in Fig. 1 (right panel) was the only possibility to construct a sound model compatible with the spin-labeling results (9) and with the solution scattering data. The modeling in the form of a grid search permitted us to systematically explore plausible dimeric configurations. An automated rigid body refinement would have been a better option for larger proteins (42), in which the influence of the bound solvent scattering is less pronounced.

The present study is not the first example of proteins with similar tertiary structures but totally different quaternary structures. In particular, tertiary structures of monomeric alpha  and beta  chemokines (e.g. interleukin-8 and human macrophage inflammatory protein-1beta ) are very similar, but the dimers are formed by different sets of residues (43). One should also mention a number of thiamine diphosphate-dependent enzymes (transketolase, pyruvate oxidase, and pyruvate decarboxylase) consisting of identical or nearly identical monomers with molecular masses of about 60 kDa that form very different biologically active dimers and tetramers (42).

The proposed model of the alpha -crystallin domain dimer displays a potentially flexible dimer interface. This flexibility may be the reason why our protein crystallization attempts were not successful, despite extensive trials.4 The flexibility might also be an essential property enabling variable sizes and compositions of the multimeric complex of alpha B-crystallin and yielding mixed sHSP species (i.e. alpha A-crystallin, alpha B-crystallin, and HSP27) in a single hetero-oligomeric complex (44). It should be stressed that the potential flexibility of the protein is problematic for crystallographic analysis but not for solution scattering modeling (the experimental scattering pattern corresponds to an average position of the monomers).

The dimer interface in the proposed model contains the residue Arg-116 that causes autosomal dominant congenital cataract in humans when mutated to Cys. Circular dichroism and 1,1'-bi(4-anilino)naphtalene-5,5'-disulfonic acid fluorescence spectra indicate that R116C alpha A-crystallin is structurally different from the wild type protein (45). Arg-116 is an identically conserved residue between alpha A- and alpha B-crystallin. According to the present model, this residue plays an essential role in dimerization, and detrimental effects on the quaternary structure and biological activity can be expected after mutation.


    ACKNOWLEDGEMENTS

We thank John Clark and Paul Muchowski for supplying plasmid alpha B57+pET16b and Santi Canela for technical assistance.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence may be addressed: European Molecular Biology Laboratory (EMBL), EMBL Hamburg Outstation, c/o Deutsches Elektronen Synchrotron, Notkestrasse 85, D-22603 Hamburg, Germany. Tel.: 49-40-89902-118; Fax: 49-40-89902-149; E-mail: Feil@EMBL-Hamburg.DE.

** To whom correspondence may be addressed: European Molecular Biology Laboratory (EMBL), EMBL Hamburg Outstation, c/o Deutsches Elektronen Synchrotron, Notkestrasse 85, D-22603 Hamburg, Germany. Tel.: 49-40-89902-125; Fax: 49-40-89902-149; E-mail: Svergun@EMBL-Hamburg.DE.

Published, JBC Papers in Press, January 12, 2001, DOI 10.1074/jbc.M010856200

2 D. I. Svergun and M. H. J. Koch, unpublished data.

3 M. Malfois and D. I. Svergun, manuscript in preparation.

4 I. K. Feil, J. Hendle, and H. van der Zandt, unpublished results.


    ABBREVIATIONS

The abbreviations used are: sHSP, small small heat-shock protein; ADH, alcohol dehydrogenase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Veretout, F., Delaye, M., and Tardieu, A. (1989) J. Mol. Biol. 205, 713-728[Medline] [Order article via Infotrieve]
2. Clark, J. I., and Muchowski, P. J. (2000) Curr. Opin. Struct. Biol. 10, 52-59[CrossRef][Medline] [Order article via Infotrieve]
3. Haley, D. A., Horwitz, J., and Stewart, P. L. (1998) J. Mol. Biol. 277, 27-35[CrossRef][Medline] [Order article via Infotrieve]
4. Lindner, R. A., Kapur, A., and Carver, J. A. (1997) J. Biol. Chem. 272, 27722-27729[Abstract/Free Full Text]
5. Rajaraman, K., Raman, B., Ramakrishna, T., and Rao, C. M. (1998) Biochem. Biophys. Res. Commun. 249, 917-921[CrossRef][Medline] [Order article via Infotrieve]
6. Das, K. P., Petrash, J. M., and Surewicz, W. K. (1996) J. Biol. Chem. 271, 10449-10452[Abstract/Free Full Text]
7. Kantorow, M., Horwitz, J., van Boekel, M. A., de Jong, W. W., and Piatigorsky, J. (1995) J. Biol. Chem. 270, 17215-17220[Abstract/Free Full Text]
8. Merck, K. B., Horwitz, J., Kersten, M., Overkamp, P., Gaestel, M., Bloemendal, H., and de Jong, W. W. (1993) J. Biol. Chem. 268, 1046-1052[Abstract/Free Full Text]
9. Berengian, A. R., Parfenova, M., and McHaourab, H. S. (1999) J. Biol. Chem. 274, 6305-6314[Abstract/Free Full Text]
10. Haley, D. A., Bova, M. P., Huang, Q. L., McHaourab, H. S., and Stewart, P. L. (2000) J. Mol. Biol. 298, 261-272[CrossRef][Medline] [Order article via Infotrieve]
11. Kim, K. K., Kim, R., and Kim, S. H. (1998) Nature 394, 595-599[CrossRef][Medline] [Order article via Infotrieve]
12. Muchowski, P. J., Wu, G. J., Liang, J. J., Adman, E. T., and Clark, J. I. (1999) J. Mol. Biol. 289, 397-411[CrossRef][Medline] [Order article via Infotrieve]
13. Feigin, L. A., and Svergun, D. I. (1987) Structure Analysis by Small-angle X-ray and Neutron Scattering , Plenum Press, New York
14. Svergun, D. I., Barberato, C., Koch, M. H., Fetler, L., and Vachette, P. (1997) Proteins 27, 110-117[CrossRef][Medline] [Order article via Infotrieve]
15. Aleshin, A. E., Malfois, M., Liu, X., Kim, C. S., Fromm, H. J., Honzatko, R. B., Koch, M. H., and Svergun, D. I. (1999) Biochemistry 38, 8359-8366[CrossRef][Medline] [Order article via Infotrieve]
16. Ashton, A. W., Boehm, M. K., Gallimore, J. R., Pepys, M. B., and Perkins, S. J. (1997) J. Mol. Biol. 272, 408-422[CrossRef][Medline] [Order article via Infotrieve]
17. Krueger, J. K., Olah, G. A., Rokop, S. E., Zhi, G., Stull, J. T., and Trewhella, J. (1997) Biochemistry 36, 6017-6023[CrossRef][Medline] [Order article via Infotrieve]
18. Svergun, D. I., Aldag, I., Sieck, T., Altendorf, K., Koch, M. H., Kane, D. J., Kozin, M. B., and Gruber, G. (1998) Biophys. J. 75, 2212-2219[Abstract/Free Full Text]
19. Horwitz, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10449-10453[Abstract]
20. Stafford, W. F. d. (1992) Anal. Biochem. 203, 295-301[Medline] [Order article via Infotrieve]
21. Philo, J. S. (1997) Biophys. J. 72, 435-444[Abstract]
22. Demeler, B., Saber, H., and Hansen, J. C. (1997) Biophys. J. 72, 397-407[Abstract]
23. Kuntz, I. D., Jr., and Brassfield, T. S. (1971) Arch. Biochem. Biophys. 142, 660-664[Medline] [Order article via Infotrieve]
24. Koch, M. H. J., and Bordas, J. (1983) Nucl. Instrum. Meth. 203, 461-469
25. Boulin, C., Kempf, R., Koch, M. H. J., and McLaughlin, S. M. (1986) Nucl. Instrum. Meth. A249, 399-407
26. Boulin, C. J., Kempf, R., Gabriel, A., and Koch, M. H. J. (1988) Nucl. Instrum. Meth. A269, 312-320
27. Gabriel, A., and Dauvergne, F. (1982) Nucl. Instrum. Meth. 201, 223-224
28. Svergun, D. I. (1993) J. Appl. Crystallogr. 26, 258-267[CrossRef]
29. Svergun, D. I., Semenyuk, A. V., and Feigin, L. A. (1988) Acta Crystallogr. A44, 244-250[CrossRef]
30. Svergun, D. I. (1992) J. Appl. Crystallogr. 25, 495-503[CrossRef]
31. Porod, G. (1982) in Small-angle X-ray Scattering (Glatter, O. , and Kratky, O., eds) , pp. 17-51, Academic Press, London
32. Svergun, D. I., Barberato, C., and Koch, M. H. J. (1995) J. Appl. Crystallogr. 28, 768-773[CrossRef]
33. Jones, T. A., Zou, J.-T., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr A. A47, 110-119[CrossRef][Medline] [Order article via Infotrieve]
34. Muchowski, P. J., Hays, L. G., Yates, J. R., III, and Clark, J. I. (1999) J. Biol. Chem. 274, 30190-30195[Abstract/Free Full Text]
35. Siezen, R. J., and Argos, P. (1983) Biochim. Biophys. Acta 748, 56-67[Medline] [Order article via Infotrieve]
36. De Jong, W. W., Caspers, G. J., and Leunissen, J. A. (1998) Int. J. Biol. Macromol. 22, 151-162[CrossRef][Medline] [Order article via Infotrieve]
37. Mornon, J. P., Halaby, D., Malfois, M., Durand, P., Callebaut, I., and Tardieu, A. (1998) Int. J. Biol. Macromol. 22, 219-227[CrossRef][Medline] [Order article via Infotrieve]
38. Kokke, B. P., Leroux, M. R., Candido, E. P., Boelens, W. C., and de Jong, W. W. (1998) FEBS Lett. 433, 228-232[CrossRef][Medline] [Order article via Infotrieve]
39. Merck, K. B., De Haard-Hoekman, W. A., Oude Essink, B. B., Bloemendal, H., and De Jong, W. W. (1992) Biochim. Biophys. Acta 1130, 267-276[Medline] [Order article via Infotrieve]
40. Leroux, M. R., Melki, R., Gordon, B., Batelier, G., and Candido, E. P. (1997) J. Biol. Chem. 272, 24646-24656[Abstract/Free Full Text]
41. Ehrnsperger, M., Lilie, H., Gaestel, M., and Buchner, J. (1999) J. Biol. Chem. 274, 14867-14874[Abstract/Free Full Text]
42. Svergun, D. I., Petoukhov, M. V., Koch, M. H. J., and König, S. (2000) J. Biol. Chem. 275, 297-303[Abstract/Free Full Text]
43. Clore, G. M., and Gronenborn, A. M. (1995) FASEB J. 9, 57-62[Abstract/Free Full Text]
44. Bova, M. P., McHaourab, H. S., Han, Y., and Fung, B. K. (2000) J. Biol. Chem. 275, 1035-1042[Abstract/Free Full Text]
45. Shroff, N. P., Cherian-Shaw, M., Bera, S., and Abraham, E. C. (2000) Biochemistry 39, 1420-1426[CrossRef][Medline] [Order article via Infotrieve]
46. Hutchinson, E. G., and Thornton, J. M. (1996) Protein Sci. 5, 212-220[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.